- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01085058
Predictive Value of the "Cytocapacity Test" Patients With Lymphoproliferative Diseases and High-dose Therapy (CU01)
Predictive Value of the "Cytocapacity Test" Following a Single-dose of rHu-G-CSF in Patients With Lymphoproliferative Diseases and High-dose Therapy
This investigator initiated trial was a prospective, open, single-arm, diagnostic-prognostic study. Patients who received high-dose therapy with autologous stem cell transplantation for the treatment of their lymphoproliferative disease were included into the study.
After completion of the high-dose therapy (day -2 with respect to the stem cell transplantation) the first blood sample A for the cytocapacity test with determination of leukocytes and neutrophils was taken in the evening of day -1. Directly thereafter the study medication was administered. The second blood sample B for the cytocapacity test with determination of leukocytes and neutrophils was taken in the morning of day 0, 12-14 hours after administration of the study medication. Thereafter the stem cell re-infusion was performed.
The primary objective of this study was to show that the cytocapacity test with lenograstim is a useful predictive tool with respect to the risk of post-transplant complications and prolonged myelosuppression, typically occurring after high-dose chemotherapy.
The primary variables were:
- the rate of patients with documented infections
- the time to platelet engraftment
Study Overview
Status
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 2
- Phase 3
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Presence of histologically proven lymphoproliferative disease specified as Hodgkin's disease, non-Hodgkin's lymphoma (NHL) or multiple myeloma
- Indication of high-dose therapy and autologous peripheral blood stem cell transplantation
- Availability of a sufficient amount of blood stem cells (CD34+ cells >= 2.0 x 106/kg)
- Age between 18 and 70 years
- High-dose therapy with one of the following high-dose regimes: Melphalan 140 mg/m2 or 200 mg/m2, BEAM, BEAC, BUCY or CBV (the last permitted according to amendment 2, see Section 9.8.1)
- Patient's written consent to participation in this trial
Exclusion Criteria:
- Previous high-dose therapy and blood stem cell transplantation except for melphalan 140 mg/m2 or 200 mg/m2 in patients with multiple myeloma who did not participate in the cytocapacity test previously (according to amendment 2, see Section 9.8.1).
- Known intolerance to lenograstim
- Out-patient therapy following high-dose therapy and blood stem cell transplantation
- Myocardial infarction < 6 months prior to inclusion into the study
- Cardiac arrhythmias Lown IV b
- Clinically manifest cardiac insufficiency (> NYHA II)
- Renal insufficiency with serum creatinine > 2 mg%
- Hepatic diseases with elevated levels of transaminases and bilirubin greater than 3-fold above normal
- Severe infections (HIV, Hepatitis B/C)
- Severe psychiatric diseases
- Non-curative treatment of other malignoma within the past 5 years
- Pregnant women or women breast-feeding
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: A: lenograstim
total group
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
---|
Incidence of infections
|
Time to platelet engraftment
|
Collaborators and Investigators
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Cardiovascular Diseases
- Vascular Diseases
- Immune System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Lymphatic Diseases
- Immunoproliferative Disorders
- Hematologic Diseases
- Hemorrhagic Disorders
- Hemostatic Disorders
- Paraproteinemias
- Blood Protein Disorders
- Neoplasms, Plasma Cell
- Lymphoma
- Multiple Myeloma
- Hodgkin Disease
- Lymphoma, Non-Hodgkin
- Lymphoproliferative Disorders
- Physiological Effects of Drugs
- Immunologic Factors
- Adjuvants, Immunologic
- Lenograstim
Other Study ID Numbers
- WISP_CU01
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hodgkin's Disease
-
University Hospital, BrestCompletedDiagnostic Imaging | Relapsed Non Hodgkin Lymphoma | Relapsed Hodgkin's Disease, Adult | Malignant Lymphoma
-
Stanford UniversityNational Institute of Allergy and Infectious Diseases (NIAID); National Institutes...CompletedLymphoma | Hodgkin's Lymphoma | Hodgkin DiseaseUnited States
-
Hospital JP GarrahanHospital Pereyra Rosell, Montevideo, UruguayRecruitingPediatric Hodgkin's DiseaseArgentina
-
Bayside HealthCompletedNon-Hodgkin's Lymphoma | Hodgkin's DiseaseAustralia
-
Bayside HealthCompletedNon-Hodgkin's Lymphoma | Hodgkin's DiseaseAustralia
-
National Cancer Institute (NCI)CompletedNon Hodgkin's Lymphoma | Hodgkin's DiseaseUnited States
-
Dana-Farber Cancer InstituteBeth Israel Deaconess Medical Center; Brigham and Women's Hospital; MedImmune...CompletedLymphoma | Non-Hodgkin's Lymphoma | Hodgkin's DiseaseUnited States
-
Baylor College of MedicineNational Cancer Institute (NCI); National Institutes of Health (NIH); The Methodist... and other collaboratorsRecruitingLymphoma | Non-Hodgkin's Lymphoma | Hodgkin's Disease | Lymphoproliferative DiseaseUnited States
-
Genzyme, a Sanofi CompanyCompletedTransplantation | Lymphoma (Non-Hodgkin's Lymphoma) | Hodgkin's Disease or Multiple Myeloma | Front Line MobilizationNetherlands, France, Germany, Sweden, Spain, Italy, United Kingdom
-
University Health Network, TorontoCompletedHodgkin's Lymphoma | Non Hodgkin's LymphomaCanada
Clinical Trials on lenograstim
-
DERSHENG SUNUnknown
-
University of PisaUnknownG-CSF, Multiple Myeloma, Febrile Episode, Filgrastim, Leograstim
-
Asan Medical CenterUnknownMultiple MyelomaKorea, Republic of
-
SanofiCompleted
-
Chang Gung Memorial HospitalRecruitingNeutropenia | Pediatric Cancer | G-CSF | Lenograstim | FilgrastimTaiwan
-
Deutsches Herzzentrum MuenchenElse Kröner Fresenius Foundation; Wilhelm Sander Foundation; Schulz FoundationCompletedMyocardial InfarctionGermany
-
Barts & The London NHS TrustUniversity College London Hospitals; Royal Brompton & Harefield NHS Foundation...CompletedDilated CardiomyopathyUnited Kingdom
-
National Institute of Allergy and Infectious Diseases...Completed
-
Azienda Ospedaliera San Giovanni BattistaUnknown